Discover
CMMB
Chemomab Therapeutics Ltd.
1.70
1 x 1.79
1 x 1.92
bid
ask
+
0.08
4.94%
1 @ 04:15 AM
1.80 +0.10 (5.88%)
| Ytd | 3.03% | |
| 1y | -63.36% |
1.61
day range
1.75
1.35
52 week range
4.92
| Open | 1.63 | Prev Close | 1.62 | Low | 1.61 | High | 1.75 | Mkt Cap | 12.24M |
| Vol | 62.14K | Avg Vol | 43.54K | EPS | -1.12 | P/E | N/A | Forward P/E | -41.25 |
| Beta | 0.30 | Short Ratio | 1.15 | Inst. Own | 27.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-25 | 50-d Avg | 1.69 | 200-d Avg | 2.06 | 1yr Est | 8.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.2 | -0.2 | N/A | N/A |
| 2024-08-21 | 2024-06 | -0.2 | -0.26 | -0.06 | -30.00% |
| 2024-08-21 | 2024-06 | -0.2 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.2 | -0.28 | -0.08 | -40.00% |
| 2024-05-09 | 2024-03 | -0.2 | N/A | N/A | N/A |
| 2024-03-07 | 2023-12 | -0.4 | -0.26 | 0.14 | 35.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-15 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-05-13 | Maxim Group | Upgrade | Buy | |
| 2024-05-06 | Oppenheimer | Upgrade | Perform | Outperform |
| 2024-03-08 | Oppenheimer | Upgrade | Perform | Perform |
| 2023-10-06 | Roth MKM | Upgrade | Buy | |
| 2023-06-07 | Oppenheimer | Downgrade | Outperform | Perform |
Profile
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-01-02 | MOR GEORGE ADI | Officer and Director | 0.00 | Sale |
| 2023-01-02 | ORBIMED ISRAEL GP LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Orbimed Advisors LLC. | 1.74M | 2.87M | 9.23% |
| 2024-09-29 | Sphera Funds Management Ltd. | 1.21M | 2.00M | 6.44% |
| 2024-09-29 | Yelin Lapidot Holdings Management Ltd. | 809.72K | 1.34M | 4.29% |
| 2024-09-29 | Morgan Stanley | 402.27K | 663.75K | 2.13% |
| 2024-09-29 | Ikarian Capital, LLC | 213.39K | 352.10K | 1.13% |
| 2024-09-29 | Two Sigma Securities, LLC | 39.94K | 65.90K | 0.21% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-06-29 | Blackstone Alternative Multi-Strategy Fund | 200.00 | 329.00 | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 4 | 2025-08-26 |
| 1 : 16 | 2021-03-17 |